last posts

Global Merchant API Market Outlook to 2027

techsm5

company logo

company logo

Global Merchant API Market

Global Merchant API Market

Global Merchant API Market

Dublin, Jan. 06, 2023 (GLOBE NEWSWIRE) — The “Global Merchant API Market: Analysis by Molecular Type, Segment, Type, Synthesis Type, End User, Region Size and Trends with COVID Impact -19 and forecast to 2027″ report has been added to from ResearchAndMarkets.com offer.

Global Merchant API Market was valued at USD 79.50 Billion in 2021. The market value is expected to reach USD 119.11 Billion by 2027.

Merchant API (or Contract Manufacturing) sits within the broader pharmaceutical value chain and encompasses all activities related to the development and manufacturing of Active Pharmaceutical Ingredients (APIs) for both clinical product trials and commercial products.

There has been an increase in willingness, especially from small pharmaceutical and biotechnology companies, to collaborate with specialized entities due to the expertise and equipment required to manufacture the compounds.

Additionally, pharmaceutical companies are increasingly focusing on core capabilities such as R&D and marketing, leaving the manufacturing side of the process to specialized entities.

Thus, merchant API market growth has increased owing to the increase in pharmaceutical outsourcing to improve margins and potentially shorten time to market. The market is expected to grow at a CAGR of approx. 7% during the forecast period 2022-2027.

Market dynamics:

  • Growth Drivers: The growth of the global merchant API market is expected to be supported by numerous growth drivers such as increasing incidence of chronic and lifestyle related diseases, aging population, rising healthcare expenditures , the increase in research and development expenditure, the growth of the pharmaceutical industry, the growing trend towards pharmaceutical outsourcing, and many other factors. Contract manufacturing offers many benefits to associates as it provides them with a supply of pharmaceutical products from clinical production to commercial manufacturing under Good Manufacturing Practices (GMP) manufacturing operations. Apart from this, the companies get time and financial assistance to work on selling and marketing products instead of just focusing on the manufacturing process of drugs. Thus, due to these factors, the trend towards outsourcing has increased, which has positively influenced the growth of the merchant API market.

  • Challenges: However, market growth would be negatively affected by various challenges such as strict laws and regulations, lack of transparency and loss of control, etc.

  • Trends: The market is expected to grow at a rapid rate over the forecast period, owing to various recent trends such as increasing use of artificial intelligence, approval of new drugs, increasing expiration of patents, etc New and innovative drugs expand treatment options, for example, for previously unmet needs or new population targets (eg children), increasing the number of drugs consumed. The need for APIs is increasing as more and more drugs are approved, thus companies outsource the manufacturing of APIs to manufacture the drugs more cost effectively. Thus, the demand for merchant APIs is expected to increase in the coming years due to the increase in new drug approvals.

COVID-19 impact analysis and way forward:

In 2020, global merchant APIs saw slower growth. A decline in volume demand for pharmaceuticals was observed in several areas, with lower rates of physician visits and new diagnoses. However, many other contract manufacturing organizations have seen a significant increase in demand related to new COVID vaccines and therapeutic projects. A large spike in the demand for new drugs has led to an increase in the manufacture, export and import of APIs, thereby leading to an average increase in the prices of API products and intermediates. Moreover, favorable policies and initiatives taken by various governments are expected to facilitate the production of APIs in the long term, which would support the growth of the merchant API market in the post-COVID era.

Competitive Landscape:

The global merchant API market is highly fragmented. Key Players of Global Merchant API Market are:

  • Pfizer Inc. (Pfizer CenterOne)

  • Bachem Holding AG

  • Thermo Fisher Scientific Inc.

  • Teva Pharmaceutical Industries Ltd. (Teva API)

  • Sanofi (EuroAPI)

  • Siegfried Holding AG

  • Lonza Group AG

  • PolyPeptide Group SA

  • Divi Laboratories Limited

  • Centrist Pharmaceuticals

  • Cambrex

  • Fabbrica Italiana Sintetici

To stay ahead of the competition, companies in the market carry out regular R&D operations. In order to stay ahead of the competition, companies operating in the global market should also turn to aggressive expansion methods including mergers, acquisitions and strategic alliances.

For example, in 2022, Bachem Group announced the signing of a new work order for the delivery of large volumes of peptides over a five-year period from 2025 to 2029.

On the other hand, Sanofi and Innovent Biologics announced a collaboration to bring innovative medicines to patients in China with difficult-to-treat cancers. Additionally, Siegfried announced that the company has decided to expand the collaboration with Novavax, a US-based biopharmaceutical company, for the aseptic filling and finishing of Novavax’s protein-based coronavirus vaccine Nuvaxovid.

In 2021, Lonza held a 2.58% share of the global merchant API market, while in the CDMO market, Lonza held a 4.6% market share.

Report attribute

Details

Number of pages

152

Forecast period

2022 – 2027

Estimated market value (USD) in 2022

$85.04 billion

Expected market value (USD) by 2027

$119.11 billion

Compound annual growth rate

7.0%

Regions covered

Global

Main topics covered:

1. Summary

2. Presentation
2.1 Active Pharmaceutical Ingredients (APIs): An Overview
2.1.1 Introduction to CDMOs and API
2.1.2 Pharmaceutical value chain
2.2 Merchant API: an overview
2.2.1 Introduction to Merchant API
2.2.2 Merchant API Advantages and Disadvantages
2.3 Merchant API Segmentation: An Analysis
2.3.1 Merchant API segmentation

3. Global Market Analysis
3.1 Global Merchant API Market: An Analysis
3.1.1 Global Merchant API Market: An Overview
3.1.2 Global Merchant API Market by Value
3.1.3 Global Commercial API Market by Molecular Type (Small Molecule and Large Molecule)
3.1.4 Global Merchant API Market by Segment (CDMO and API Solutions)
3.1.5 Global Merchant API Market by Type (Innovative API and Generic API)
3.1.6 Global Commercial API Market by Synthesis Type (Synthetic and Biotech)
3.1.7 Global Merchant API Market by Region (North America, Asia-Pacific, Europe and Rest of the World)
3.2 Global Merchant API Market: Molecular Type Analysis
3.2.1 Global Merchant API Market by Molecular Type: An Overview
3.2.2 Global Small Molecule Merchant API Market by Value
3.2.3 Global Large Molecule Merchant API Market by Value
3.3 Global Merchant API Market: Segment Analysis
3.3.1 Global Merchant API Market by Segment: An Overview
3.3.2 Global Merchant API CDMO Market by Value
3.3.3 Global CDMO Merchant API Market by Molecular Type (Small Molecule and Large Molecule)
3.3.4 Global Merchant API CDMO Molecular Type Market by Value
3.3.5 Global Merchant API CDMO Market by End User (Peptides, Oligos and Others)
3.3.6 Global CDMO Merchant API End User Market by Value
3.3.7 Global Merchant API Solutions Market by Value
3.4 Global Merchant API Market: Type Analysis
3.4.1 Global Merchant API Market by Type: An Overview
3.4.2 Global Innovative Merchant API Market by Value
3.4.3 Global Generic Merchant API Market by Value
3.5 Global Merchant API Market: Type of Summary Analysis
3.5.1 Global Merchant API Market by Type Summary: An Overview
3.5.2 Global Synthetic Merchant API Market by Value
3.5.3 Global Biotechnology Merchant API Market by Value

4. Regional Market Analysis

5. Impact of COVID-19
5.1 Impact of COVID-19 on the Global Merchant API Market
5.2 Post-COVID-19 Impact on the Global Merchant API Market

6. Market dynamics
6.1 Drivers of growth
6.1.1 Increased incidence of diabetes
6.1.2 Population aging
6.1.3 Increase in health expenditure
6.1.4 Increase in research and development expenditure
6.1.5 Growth of Pharmaceutical Industry
6.1.6 Growing Trend of Pharmaceutical Outsourcing
6.2 Challenges
6.2.1 Strict laws and regulations
6.2.2 Lack of transparency and loss of control
6.3 Market trends
6.3.1 Increasing use of artificial intelligence
6.3.2 New Drug Approvals
6.3.3 Increased patent expiration
6.3.4 High Potency Active Pharmaceutical Ingredients (HPAPI) Growth

7. Competitive Landscape
7.1 Global Merchant API Players by Market Share
7.2 Global Merchant API CDMO Players by Market Share
7.3 Global Peptide Merchant API CDMO Players by Market Share
7.4 Global Merchant Oligos API CDMO Players by Market Share

8. Company Profiles
8.1 Pfizer Inc. (Pfizer CenterOne)
8.1.1 Overview of activities
8.1.2 Operating segments
8.1.3 Business Strategies
8.2 Bachem Holding AG
8.2.1 Overview of activities
8.2.2 Net sales by product categories
8.2.3 Business strategies
8.3 Thermo Fisher Scientific Inc.
8.3.1 Company Overview
8.3.2 Operating segments
8.3.3 Business strategy
8.4 Teva Pharmaceutical Industries Ltd. (Teva API)
8.4.1 Business Overview
8.4.2 Operating segments
8.4.3 Business Strategies
8.5 Sanofi (EuroAPI)
8.5.1 Company Overview
8.5.2 Operating segments
8.5.3 Business Strategies
8.6 Siegfried Holding AG
8.6.1 Company Overview
8.6.2 Net sales by product group
8.6.3 Business Strategies
8.7 Lonza Group AG
8.7.1 Company Overview
8.7.2 Operating segments
8.7.3 Business Strategy
8.8 PolyPeptide Group SA
8.8.1 Company Overview
8.8.2 Operating segments
8.8.3 Business Strategies
8.9 Divi Laboratories Limited
8.9.1 Company Overview
8.9.2 Revenue by Region
8.10 Centrient Pharmaceuticals
8.10.1 Company Overview
8.10.2 Business Strategies
8.11 Cambrex
8.11.1 Company Overview
8.11.2 Business strategy
8.12 Fabbrica Italiana Sintetici
8.12.1 Company Overview

For more information on this report visit https://www.researchandmarkets.com/r/ddl6e2

Enclosed

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

techsm5

Comments



Font Size
+
16
-
lines height
+
2
-